Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
424 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Metastatic Colorectal Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Metastatic Colorectal Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Colorectal Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Colorectal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Colorectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Metastatic Colorectal Cancer Overview 11 Therapeutics Development 12 Pipeline Products for Metastatic Colorectal Cancer - Overview 12 Pipeline Products for Metastatic Colorectal Cancer - Comparative Analysis 13 Metastatic Colorectal Cancer - Therapeutics under Development by Companies 14 Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 19 Metastatic Colorectal Cancer - Pipeline Products Glance 20 Late Stage Products 20 Clinical Stage Products 21 Early Stage Products 22 Metastatic Colorectal Cancer - Products under Development by Companies 23 Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes 28 Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development 29 Bristol-Myers Squibb Company 29 Boehringer Ingelheim GmbH 30 F. Hoffmann-La Roche Ltd. 31 Amgen Inc. 32 AstraZeneca PLC 33 Eli Lilly and Company 34 Genentech, Inc. 35 Bavarian Nordic A/S 36 Merck & Co., Inc. 37 Takeda Pharmaceutical Company Limited 38 Celltrion, Inc. 39 Millennium Pharmaceuticals, Inc. 40 Novartis AG 41 Biocon Limited 42 Nippon Kayaku Co., Ltd. 43 Pfizer Inc. 44 Astex Pharmaceuticals, Inc. 45 Taiho Pharmaceutical Co., Ltd. 46 Teva Pharmaceutical Industries Limited 47 Exelixis, Inc. 48 Celgene Corporation 49 Bayer AG 50 Incyte Corporation 51 Merck KGaA 52 Alchemia Limited 53 Immunomedics, Inc. 54 Oncolytics Biotech Inc. 55 Regeneron Pharmaceuticals, Inc. 56 Mologen AG 57 Synta Pharmaceuticals Corp. 58 Panacea Biotec Limited 59 Morphotek, Inc. 60 Actinium Pharmaceuticals, Inc. 61 Glycotope GmbH 62 Hutchison MediPharma Limited 63 immatics biotechnologies GmbH 64 MacroGenics, Inc. 65 TetraLogic Pharmaceuticals 66 Merrimack Pharmaceuticals, Inc. 67 Syndax Pharmaceuticals, Inc. 68 Globeimmune, Inc. 69 AB Science 70 CureTech Ltd. 71 Biothera, Inc. 72 Medical Enzymes AG 73 Oncozyme Pharma Inc. 74 Genor BioPharma Co., Ltd. 75 RadioRx, Inc. 76 Karyopharm Therapeutics, Inc. 77 Immodulon Therapeutics Ltd. 78 Inbiopro Solutions Pvt. Ltd. 79 Kadmon Corporation, LLC 80 Epirus Biopharmaceuticals, Inc. 81 AlphaMab Co., Ltd 82 Metastatic Colorectal Cancer - Therapeutics Assessment 83 Assessment by Monotherapy Products 83 Assessment by Combination Products 84 Assessment by Target 85 Assessment by Mechanism of Action 91 Assessment by Route of Administration 97 Assessment by Molecule Type 99 Drug Profiles 102 panitumumab - Drug Profile 102 regorafenib - Drug Profile 105 irinotecan hydrochloride - Drug Profile 107 ramucirumab - Drug Profile 109 (tipiracil + trifluridine) - Drug Profile 114 MGN-1703 - Drug Profile 116 masitinib - Drug Profile 118 (tegafur + gimeracil + oteracil) - Drug Profile 121 etirinotecan pegol - Drug Profile 124 Novaferon - Drug Profile 127 trebananib - Drug Profile 129 entinostat - Drug Profile 133 abituzumab - Drug Profile 137 MK-2206 - Drug Profile 139 sorafenib tosylate - Drug Profile 142 axitinib - Drug Profile 146 gedatolisib - Drug Profile 149 selumetinib sulfate - Drug Profile 151 SGI-110 - Drug Profile 154 HMPL-013 - Drug Profile 157 IMA-910 - Drug Profile 158 futuximab - Drug Profile 160 ganitumab - Drug Profile 162 paclitaxel - Drug Profile 165 pimasertib hydrochloride - Drug Profile 168 ganetespib - Drug Profile 170 ruxolitinib phosphate - Drug Profile 174 pelareorep - Drug Profile 178 ontuxizumab - Drug Profile 182 nintedanib - Drug Profile 184 GlutaDON - Drug Profile 187 pentamidine isethionate - Drug Profile 189 pidilizumab - Drug Profile 191 GI-4000 - Drug Profile 193 buparlisib hydrochloride - Drug Profile 195 NK-012 - Drug Profile 199 imgatuzumab - Drug Profile 201 duligotuzumab - Drug Profile 203 Monoclonal Antibody Conjugate Targeting CEA for Metastatic Liver and Colorectal Cancer - Drug Profile 205 birinapant - Drug Profile 206 IMMU-130 - Drug Profile 208 IMM-101 - Drug Profile 209 RRx-001 - Drug Profile 210 Imprime PGG - Drug Profile 212 Cell Therapy for Metastatic Colorectal Cancer - Drug Profile 216 CV-301 - Drug Profile 217 RG-7221 - Drug Profile 218 rilotumumab - Drug Profile 219 fluorouracil - Drug Profile 221 sapitinib - Drug Profile 222 pexastimogene devacirepvec - Drug Profile 224 CEP-32496 - Drug Profile 226 BYL-719 - Drug Profile 227 Enadenotucirev - Drug Profile 229 encorafenib - Drug Profile 231 Vaccine for Metastatic Colorectal Cancer - Drug Profile 232 RXDX-101 - Drug Profile 233 Stem Cell Therapy for Oncology - Drug Profile 235 motesanib diphosphate - Drug Profile 236 cetuximab biobetter - Drug Profile 240 cabozantinib s-malate - Drug Profile 241 irinotecan sucrosofate liposomal - Drug Profile 244 TF-2 - Drug Profile 246 erismodegib - Drug Profile 248 PF-03446962 - Drug Profile 251 urelumab - Drug Profile 252 luminespib - Drug Profile 254 Monoclonal Antibody Conjugate Targeting CEA for Metastatic Liver and Colorectal Cancer - Drug Profile 257 ziv-aflibercept - Drug Profile 259 PD-0325901 + PF-05212384 - Drug Profile 263 MK-8353 - Drug Profile 264 selinexor - Drug Profile 265 bevacizumab biosimilar - Drug Profile 267 bevacizumab biosimilar - Drug Profile 268 bevacizumab biosimilar - Drug Profile 269 cetuximab biosimilar - Drug Profile 270 bevacizumab biosimilar - Drug Profile 271 IBPM-002BZ - Drug Profile 272 Actimab-C - Drug Profile 273 MLN-0264 - Drug Profile 274 bevacizumab biosimilar - Drug Profile 275 bevacizumab biosimilar - Drug Profile 276 cetuximab biosimilar - Drug Profile 277 bevacizumab biosimilar - Drug Profile 278 bevacizumab biosimilar - Drug Profile 279 MGD-007 - Drug Profile 280 cetuximab biosimilar - Drug Profile 281 Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile 282 cetuximab biosimilar - Drug Profile 283 bevacizumab biosimilar - Drug Profile 284 Monoclonal Antibody to Inhibit VEGFR-2 for Colorectal Cancer - Drug Profile 285 Metastatic Colorectal Cancer - Recent Pipeline Updates 286 Metastatic Colorectal Cancer - Dormant Projects 405 Metastatic Colorectal Cancer - Discontinued Products 407 Metastatic Colorectal Cancer - Product Development Milestones 408 Featured News & Press Releases 408 Appendix 417 Methodology 417 Coverage 417 Secondary Research 417 Primary Research 417 Expert Panel Validation 417 Contact Us 418 Disclaimer 418
List of Tables Number of Products under Development for Metastatic Colorectal Cancer, H2 2014 18 Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H2 2014 19 Number of Products under Development by Companies, H2 2014 21 Number of Products under Development by Companies, H2 2014 (Contd..1) 22 Number of Products under Development by Companies, H2 2014 (Contd..2) 23 Number of Products under Development by Companies, H2 2014 (Contd..3) 24 Number of Products under Investigation by Universities/Institutes, H2 2014 25 Comparative Analysis by Late Stage Development, H2 2014 26 Comparative Analysis by Clinical Stage Development, H2 2014 27 Comparative Analysis by Early Stage Development, H2 2014 28 Products under Development by Companies, H2 2014 29 Products under Development by Companies, H2 2014 (Contd..1) 30 Products under Development by Companies, H2 2014 (Contd..2) 31 Products under Development by Companies, H2 2014 (Contd..3) 32 Products under Development by Companies, H2 2014 (Contd..4) 33 Products under Investigation by Universities/Institutes, H2 2014 34 Metastatic Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 35 Metastatic Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 36 Metastatic Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 37 Metastatic Colorectal Cancer - Pipeline by Amgen Inc., H2 2014 38 Metastatic Colorectal Cancer - Pipeline by AstraZeneca PLC, H2 2014 39 Metastatic Colorectal Cancer - Pipeline by Eli Lilly and Company, H2 2014 40 Metastatic Colorectal Cancer - Pipeline by Genentech, Inc., H2 2014 41 Metastatic Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 42 Metastatic Colorectal Cancer - Pipeline by Merck & Co., Inc., H2 2014 43 Metastatic Colorectal Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 44 Metastatic Colorectal Cancer - Pipeline by Celltrion, Inc., H2 2014 45 Metastatic Colorectal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 46 Metastatic Colorectal Cancer - Pipeline by Novartis AG, H2 2014 47 Metastatic Colorectal Cancer - Pipeline by Biocon Limited, H2 2014 48 Metastatic Colorectal Cancer - Pipeline by Nippon Kayaku Co., Ltd., H2 2014 49 Metastatic Colorectal Cancer - Pipeline by Pfizer Inc., H2 2014 50 Metastatic Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 51 Metastatic Colorectal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2014 52 Metastatic Colorectal Cancer - Pipeline by Teva Pharmaceutical Industries Limited., H2 2014 53 Metastatic Colorectal Cancer - Pipeline by Exelixis, Inc., H2 2014 54 Metastatic Colorectal Cancer - Pipeline by Celgene Corporation, H2 2014 55 Metastatic Colorectal Cancer - Pipeline by Bayer AG, H2 2014 56 Metastatic Colorectal Cancer - Pipeline by Incyte Corporation, H2 2014 57 Metastatic Colorectal Cancer - Pipeline by Merck KGaA, H2 2014 58 Metastatic Colorectal Cancer - Pipeline by Alchemia Limited, H2 2014 59 Metastatic Colorectal Cancer - Pipeline by Immunomedics, Inc., H2 2014 60 Metastatic Colorectal Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 61 Metastatic Colorectal Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 62 Metastatic Colorectal Cancer - Pipeline by Mologen AG, H2 2014 63 Metastatic Colorectal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 64 Metastatic Colorectal Cancer - Pipeline by Panacea Biotec Limited, H2 2014 65 Metastatic Colorectal Cancer - Pipeline by Morphotek, Inc., H2 2014 66 Metastatic Colorectal Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 67 Metastatic Colorectal Cancer - Pipeline by Glycotope GmbH, H2 2014 68 Metastatic Colorectal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2014 69 Metastatic Colorectal Cancer - Pipeline by immatics biotechnologies GmbH, H2 2014 70 Metastatic Colorectal Cancer - Pipeline by MacroGenics, Inc., H2 2014 71 Metastatic Colorectal Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2014 72 Metastatic Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 73 Metastatic Colorectal Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H2 2014 74 Metastatic Colorectal Cancer - Pipeline by Globeimmune, Inc., H2 2014 75 Metastatic Colorectal Cancer - Pipeline by AB Science, H2 2014 76 Metastatic Colorectal Cancer - Pipeline by CureTech Ltd., H2 2014 77 Metastatic Colorectal Cancer - Pipeline by Biothera, Inc., H2 2014 78 Metastatic Colorectal Cancer - Pipeline by Medical Enzymes AG, H2 2014 79 Metastatic Colorectal Cancer - Pipeline by Oncozyme Pharma Inc., H2 2014 80 Metastatic Colorectal Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2014 81 Metastatic Colorectal Cancer - Pipeline by RadioRx, Inc., H2 2014 82 Metastatic Colorectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 83 Metastatic Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2014 84 Metastatic Colorectal Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 85 Metastatic Colorectal Cancer - Pipeline by Kadmon Corporation, LLC, H2 2014 86 Metastatic Colorectal Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 87 Metastatic Colorectal Cancer - Pipeline by AlphaMab Co., Ltd, H2 2014 88 Assessment by Monotherapy Products, H2 2014 89 Assessment by Combination Products, H2 2014 90 Number of Products by Stage and Target, H2 2014 93 Number of Products by Stage and Mechanism of Action, H2 2014 99 Number of Products by Stage and Route of Administration, H2 2014 104 Number of Products by Stage and Molecule Type, H2 2014 107 Metastatic Colorectal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 292 Metastatic Colorectal Cancer - Dormant Projects, H2 2014 411 Metastatic Colorectal Cancer - Discontinued Products, H2 2014 413
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
